Ganoderma lucidum for cancer treatment: We are close but still not there

Integrative Cancer Therapies

Volumn 14, Issue 3, 2015, Pages 249-257

  Cheng, Shujie ^a   Sliva, Daniel ^a,b  

^a METHODIST RESEARCH INSTITUTE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cancer; clinical practice; cytostatic; cytotoxicity; fingerprint associated activity; Ganoderma lucidum; immunomodulation; inflammation; metastasis

Indexed keywords

GANODERMA LUCIDUM EXTRACT; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; HERBACEOUS AGENT;

AGED; ANTIINFLAMMATORY ACTIVITY; B LYMPHOCYTE; CANCER THERAPY; CASE REPORT; CHINESE MEDICINE; CLINICAL PRACTICE; CYTOSTASIS; CYTOTOXICITY; DENDRITIC CELL; DIGESTIVE SYSTEM CANCER; DRUG BIOAVAILABILITY; FEMALE; GANODERMA LUCIDUM; HEPATITIS B; HUMAN; IMMUNOMODULATION; INFLAMMATION; LARGE CELL LYMPHOMA; LIVER CELL CARCINOMA; MACROPHAGE; MALE; METASTASIS; METASTASIS INHIBITION; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; T LYMPHOCYTE; ADULT; ALTERNATIVE MEDICINE; CHEMISTRY; NEOPLASMS; PROCEDURES;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; COMPLEMENTARY THERAPIES; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; MALE; MEDICINE, CHINESE TRADITIONAL; NEOPLASMS; REISHI;

EID: 84927930764     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735414568721     Document Type: Review

References (86)

1. Ling-Sing Seow S, Naidu M, David P, Wong KH, Sabaratnam V. Potentiation of neuritogenic activity of medicinal mushrooms in rat pheochromocytoma cells. BMC Complement Altern Med. 2013 ; 13 (1). 157
2. Kim HJ, Chang WK, Kim MK, Lee SS, Choi BY. Dietary factors and gastric cancer in Korea: a case-control study. Int J Cancer. 2002 ; 97 (4). 531-535
3. Hara M, Hanaoka T, Kobayashi M, et al. Cruciferous vegetables, mushrooms, and gastrointestinal cancer risks in a multicenter, hospital-based case-control study in Japan. Nutr Cancer. 2003 ; 46 (2). 138-147
4. Shin A, Kim J, Lim SY, et al. Dietary mushroom intake and the risk of breast cancer based on hormone receptor status. Nutr Cancer. 2010 ; 62 (4). 476-483
5. Zhang M, Huang J, Xie X, Holman CD. Dietary intakes of mushrooms and green tea combine to reduce the risk of breast cancer in Chinese women. Int J Cancer. 2009 ; 124 (6). 1404-1408
6. Chen YW, Hu DJ, Cheong KL, et al. Quality evaluation of lentinan injection produced in China. J Pharm Biomed Anal. 2013 ; 78-79: 176-182
7. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014 ; 64 (1). 9-29
8. Ouhtit A, Gaur RL, Abdraboh M, et al. Simultaneous inhibition of cell-cycle, proliferation, survival, metastatic pathways and induction of apoptosis in breast cancer cells by a phytochemical super-cocktail: genes that underpin its mode of action. J Cancer. 2013 ; 4 (9). 703-715
9. Jin X, Ruiz Beguerie J, Sze DM, Chan GC. Ganoderma lucidum (Reishi mushroom) for cancer treatment. Cochrane Database Syst Rev. 2012 ; 6: CD007731
10. Radwan FF, Perez JM, Haque A. Apoptotic and immune restoration effects of ganoderic acids define a new prospective for complementary treatment of cancer. J Clin Cell Immunol. 2011 ; S3: 4
11. Sliva D. Cellular and physiological effects of Ganoderma lucidum (Reishi). Mini Rev Med Chem. 2004 ; 4 (8). 873-879
12. Sliva D. Ganoderma lucidum (Reishi) in cancer treatment. Integr Cancer Ther. 2003 ; 2 (4). 358-364
13. Paterson RR. Ganoderma - a therapeutic fungal biofactory. Phytochemistry. 2006 ; 67 (18). 1985-2001
14. Weng CJ, Yen GC. The in vitro and in vivo experimental evidences disclose the chemopreventive effects of Ganoderma lucidum on cancer invasion and metastasis. Clin Exp Metastasis. 2010 ; 27 (5). 361-369
15. Hsieh TC, Wu JM. Suppression of proliferation and oxidative stress by extracts of Ganoderma lucidum in the ovarian cancer cell line OVCAR-3. Int J Mol Med. 2011 ; 28 (6). 1065-1069
16. Wu GS, Guo JJ, Bao JL, et al. Anti-cancer properties of triterpenoids isolated from Ganoderma lucidum - a review. Expert Opin Investig Drugs. 2013 ; 22 (8). 981-992
17. Boh B, Berovic M, Zhang J, Zhi-Bin L. Ganoderma lucidum and its pharmaceutically active compounds. Biotechnol Annu Rev. 2007 ; 13: 265-301
18. Boh B. Ganoderma lucidum: a potential for biotechnological production of anti-cancer and immunomodulatory drugs. Recent Pat Anticancer Drug Discov. 2013 ; 8 (3). 255-287
19. Williams GH, Stoeber K. The cell cycle and cancer. J Pathol. 2012 ; 226 (2). 352-364
20. Villasana M, Ochoa G, Aguilar S. Modeling and optimization of combined cytostatic and cytotoxic cancer chemotherapy. Artif Intell Med. 2010 ; 50 (3). 163-173
21. Yue QX, Xie FB, Guan SH, et al. Interaction of Ganoderma triterpenes with doxorubicin and proteomic characterization of the possible molecular targets of Ganoderma triterpenes. Cancer Sci. 2008 ; 99 (7). 1461-1470
22. Thyagarajan A, Jedinak A, Nguyen H, et al. Triterpenes from Ganoderma lucidum induce autophagy in colon cancer through the inhibition of p38 mitogen-activated kinase (p38 MAPK). Nutr Cancer. 2010 ; 62 (5). 630-640
23. Cheng CR, Yue QX, Wu ZY, et al. Cytotoxic triterpenoids from Ganoderma lucidum. Phytochemistry. 2010 ; 71 (13). 1579-1585
24. Jiang J, Grieb B, Thyagarajan A, Sliva D. Ganoderic acids suppress growth and invasive behavior of breast cancer cells by modulating AP-1 and NF-kappaB signaling. Int J Mol Med. 2008 ; 21 (5). 577-584
25. Yao X, Li G, Xu H, Lu C. Inhibition of the JAK-STAT3 signaling pathway by ganoderic acid A enhances chemosensitivity of HepG2 cells to cisplatin. Planta Med. 2012 ; 78 (16). 1740-1748
26. Radwan FF, Hossain A, God JM, et al. Reduction of myeloid-derived suppressor cells and lymphoma growth by a natural triterpenoid. J Cell Biochem. 2015 ; 116 (1). 102-114
27. Wu GS, Lu JJ, Guo JJ, et al. Ganoderic acid DM, a natural triterpenoid, induces DNA damage, G1 cell cycle arrest and apoptosis in human breast cancer cells. Fitoterapia. 2012 ; 83 (2). 408-414
28. Hossain A, Radwan FF, Doonan BP, et al. A possible cross-talk between autophagy and apoptosis in generating an immune response in melanoma. Apoptosis. 2012 ; 17 (10). 1066-1078
29. Liu JQ, Wang CF, Li Y, Luo HR, Qiu MH. Isolation and bioactivity evaluation of terpenoids from the medicinal fungus Ganoderma sinense. Planta Med. 2012 ; 78 (4). 368-376
30. Li F, Wang Y, Wang X, Li J, Cui H, Niu M. Ganoderic acids suppress growth and angiogenesis by modulating the NF-kappaB signaling pathway in breast cancer cells. Int J Clin Pharmacol Ther. 2012 ; 50 (10). 712-721
31. Liu RM, Zhong JJ. Ganoderic acid Mf and S induce mitochondria mediated apoptosis in human cervical carcinoma HeLa cells. Phytomedicine. 2011 ; 18 (5). 349-355
32. Li YB, Liu RM, Zhong JJ. A new ganoderic acid from Ganoderma lucidum mycelia and its stability. Fitoterapia. 2013 ; 84: 115-122
33. Liu RM, Li YB, Zhong JJ. Cytotoxic and pro-apoptotic effects of novel ganoderic acid derivatives on human cervical cancer cells in vitro. Eur J Pharmacol. 2012 ; 681 (1-3). 23-33
34. Ruan W, Lim AH, Huang LG, Popovich DG. Extraction optimisation and isolation of triterpenoids from Ganoderma lucidum and their effect on human carcinoma cell growth. Nat Prod Res. 2014 ; 28 (24). 2264-2272
35. Jiang J, Jedinak A, Sliva D. Ganodermanontriol (GDNT) exerts its effect on growth and invasiveness of breast cancer cells through the down-regulation of CDC20 and uPA. Biochem Biophys Res Commun. 2011 ; 415 (2). 325-329
36. Jedinak A, Thyagarajan-Sahu A, Jiang J, Sliva D. Ganodermanontriol, a lanostanoid triterpene from Ganoderma lucidum, suppresses growth of colon cancer cells through ss-catenin signaling. Int J Oncol. 2011 ; 38 (3). 761-767
37. Li P, Deng YP, Wei XX, Xu JH. Triterpenoids from Ganoderma lucidum and their cytotoxic activities. Nat Prod Res. 2013 ; 27 (1). 17-22
38. Xu Z, Chen X, Zhong Z, Chen L, Wang Y. Ganoderma lucidum polysaccharides: immunomodulation and potential anti-tumor activities. Am J Chin Med. 2011 ; 39 (1). 15-27
39. Shang D, Li Y, Wang C, Wang X, Yu Z, Fu X. A novel polysaccharide from Se-enriched Ganoderma lucidum induces apoptosis of human breast cancer cells. Oncol Rep. 2011 ; 25 (1). 267-272
40. Shang D, Zhang J, Wen L, Li Y, Cui Q. Preparation, characterization, and antiproliferative activities of the Se-containing polysaccharide SeGLP-2B-1 from Se-enriched Ganoderma lucidum. J Agric Food Chem. 2009 ; 57 (17). 7737-7742
41. Li N, Hu YL, He CX, et al. Preparation, characterisation and anti-tumour activity of Ganoderma lucidum polysaccharide nanoparticles. J Pharm Pharmacol. 2010 ; 62 (1). 139-144
42. Huang CY, Chen JY, Wu JE, et al. Ling-Zhi polysaccharides potentiate cytotoxic effects of anticancer drugs against drug-resistant urothelial carcinoma cells. J Agric Food Chem. 2010 ; 58 (15). 8798-8805
43. Wang J, Zhang L, Yu Y, Cheung PC. Enhancement of antitumor activities in sulfated and carboxymethylated polysaccharides of Ganoderma lucidum. J Agric Food Chem. 2009 ; 57 (22). 10565-10572
44. Geiger TR, Peeper DS. Metastasis mechanisms. Biochim Biophys Acta. 2009 ; 1796 (2). 293-308
45. Wu GS, Song YL, Yin ZQ, et al. Ganoderiol A-enriched extract suppresses migration and adhesion of MDA-MB-231 cells by inhibiting FAK-SRC-paxillin cascade pathway. PLoS One. 2013 ; 8 (10). e76620
46. Loganathan J, Jiang J, Smith A, et al. The mushroom Ganoderma lucidum suppresses breast-to-lung cancer metastasis through the inhibition of pro-invasive genes. Int J Oncol. 2014 ; 44 (6). 2009-2015
47. Adamec J, Jannasch A, Dudhgaonkar S, Jedinak A, Sedlak M, Sliva D. Development of a new method for improved identification and relative quantification of unknown metabolites in complex samples: determination of a triterpenoid metabolic fingerprint for the in situ characterization of Ganoderma bioactive compounds. J Sep Sci. 2009 ; 32 (23-24). 4052-4058
48. Liu J, Shiono J, Shimizu K, Kukita A, Kukita T, Kondo R. Ganoderic acid DM: anti-androgenic osteoclastogenesis inhibitor. Bioorg Med Chem Lett. 2009 ; 19 (8). 2154-2157
49. Chen NH, Liu JW, Zhong JJ. Ganoderic acid Me inhibits tumor invasion through down-regulating matrix metalloproteinases 2/9 gene expression. J Pharmacol Sci. 2008 ; 108 (2). 212-216
50. Chen NH, Zhong JJ. p53 is important for the anti-invasion of ganoderic acid T in human carcinoma cells. Phytomedicine. 2011 ; 18 (8-9). 719-725
51. Weng CJ, Chau CF, Chen KD, Chen DH, Yen GC. The anti-invasive effect of lucidenic acids isolated from a new Ganoderma lucidum strain. Mol Nutr Food Res. 2007 ; 51 (12). 1472-1477
52. Weng CJ, Chau CF, Hsieh YS, Yang SF, Yen GC. Lucidenic acid inhibits PMA-induced invasion of human hepatoma cells through inactivating MAPK/ERK signal transduction pathway and reducing binding activities of NF-kappaB and AP-1. Carcinogenesis. 2008 ; 29 (1). 147-156
53. Hussain SP, Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer. 2007 ; 121 (11). 2373-2380
54. Hong KJ, Dunn DM, Shen CL, Pence BC. Effects of Ganoderma lucidum on apoptotic and anti-inflammatory function in HT-29 human colonic carcinoma cells. Phytother Res. 2004 ; 18 (9). 768-770
55. Lakshmi B, Ajith TA, Sheena N, Gunapalan N, Janardhanan KK. Antiperoxidative, anti-inflammatory, and antimutagenic activities of ethanol extract of the mycelium of Ganoderma lucidum occurring in South India. Teratog Carcinog Mutagen. 2003 ;: 85-97
56. Dudhgaonkar S, Thyagarajan A, Sliva D. Suppression of the inflammatory response by triterpenes isolated from the mushroom Ganoderma lucidum. Int Immunopharmacol. 2009 ; 9 (11). 1272-1280
57. Sliva D, Loganathan J, Jiang J, et al. Mushroom Ganoderma lucidum prevents colitis-associated carcinogenesis in mice. PLoS One. 2012 ; 7 (10). e47873
58. Joseph S, Sabulal B, George V, Antony KR, Janardhanan KK. Antitumor and anti-inflammatory activities of polysaccharides isolated from Ganoderma lucidum. Acta Pharm. 2011 ; 61 (3). 335-342
59. Lin CY, Chen YH, Lin CY, et al. Ganoderma lucidum polysaccharides attenuate endotoxin-induced intercellular cell adhesion molecule-1 expression in cultured smooth muscle cells and in the neointima in mice. J Agric Food Chem. 2010 ; 58 (17). 9563-9571
60. Lin ZB. Cellular and molecular mechanisms of immuno-modulation by Ganoderma lucidum. J Pharmacol Sci. 2005 ; 99 (2). 144-153
61. Sun LX, Lin ZB, Duan XS, et al. Polysaccharides counteract inhibition on CD71 and FasL expression by culture supernatant of B16F10 cells upon lymphocyte activation. Exp Ther Med. 2013 ; 5 (4). 1117-1122
62. Sun LX, Li WD, Lin ZB, et al. Protection against lung cancer patient plasma-induced lymphocyte suppression by Ganoderma lucidum polysaccharides. Cell Physiol Biochem. 2014 ; 33 (2). 289-299
63. Lu J, Sun LX, Lin ZB, et al. Antagonism by Ganoderma lucidum polysaccharides against the suppression by culture supernatants of B16F10 melanoma cells on macrophage. Phytother Res. 2014 ; 28 (2). 200-206
64. Guo L, Xie J, Ruan Y, et al. Characterization and immunostimulatory activity of a polysaccharide from the spores of Ganoderma lucidum. Int Immunopharmacol. 2009 ; 9 (10). 1175-1182
65. Pan K, Jiang Q, Liu G, Miao X, Zhong D. Optimization extraction of Ganoderma lucidum polysaccharides and its immunity and antioxidant activities. Int J Biol Macromol. 2013 ; 55: 301-306
66. Watanabe K, Shuto T, Sato M, et al. Lucidenic acids-rich extract from antlered form of Ganoderma lucidum enhances TNFα induction in THP-1 monocytic cells possibly via its modulation of MAP kinases p38 and JNK. Biochem Biophys Res Commun. 2011 ; 408 (1). 18-24
67. Wang X, Liu R, Sun J, et al. HPLC method for the determination and pharmacokinetic studies of four triterpenoids in rat plasma after oral administration of Ganoderma lucidum extract. Biomed Chromatogr. 2007 ; 21 (4). 389-396
68. Zhang Q, Zuo F, Nakamura N, Ma CM, Hattori M. Metabolism and pharmacokinetics in rats of ganoderiol F, a highly cytotoxic and antitumor triterpene from Ganoderma lucidum. J Nat Med. 2009 ; 63 (3). 304-310
69. Teekachunhatean S, Sadja S, Ampasavate C, Chiranthanut N, Rojanasthien N, Sangdee C. Pharmacokinetics of ganoderic acids a and f after oral administration of ling zhi preparation in healthy male volunteers. Evid Based Complement Alternat Med. 2012 ; 2012: 780892
70. Guo XY, Han J, Ye M, et al. Identification of major compounds in rat bile after oral administration of total triterpenoids of Ganoderma lucidum by high-performance liquid chromatography with electrospray ionization tandem mass spectrometry. J Pharm Biomed Anal. 2012 ; 63: 29-39
71. Cheng C, Yang M, Yu K, et al. Identification of metabolites of ganoderic acid D by ultra-performance liquid chromatography quadrupole time-of-flight mass spectrometry. Drug Metab Dispos. 2012 ; 40 (12). 2307-2314
72. Guo XY, Liu D, Ye M, et al. Structural characterization of minor metabolites and pharmacokinetics of ganoderic acid C2 in rat plasma by HPLC coupled with electrospray ionization tandem mass spectrometry. J Pharm Biomed Anal. 2013 ; 75: 64-73
73. Cheng CR, Yang M, Guan SH, et al. Pharmacokinetics of ganoderic acid D and its main metabolite by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 ; 930: 1-6
74. Guo X, Shen X, Long J, Han J, Che Q. Structural identification of the metabolites of ganoderic acid B from Ganoderma lucidum in rats based on liquid chromatography coupled with electrospray ionization hybrid ion trap and time-of-flight mass spectrometry. Biomed Chromatogr. 2013 ; 27 (9). 1177-1187
75. Cheng CR, Yang M, Yu K, et al. Metabolite identification of crude extract from Ganoderma lucidum in rats using ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 ; 941: 90-99
76. Rice PJ, Lockhart BE, Barker LA, Adams EL, Ensley HE, Williams DL. Pharmacokinetics of fungal (1-3)-beta-D-glucans following intravenous administration in rats. Int Immunopharmacol. 2004 ; 4 (9). 1209-1215
77. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 ; 359 (4). 378-390
78. Gordan JD, Chay WY, Kelley RK, Ko AH, Choo SP, Venook AP. "And what other medications are you taking?". J Clin Oncol. 2011 ; 29 (11). e288 - e291
79. Ghafar MA, Golliday E, Bingham J, Mansukhani MM, Anastasiadis AG, Katz AE. Regression of prostate cancer following administration of Genistein Combined Polysaccharide (GCP), a nutritional supplement: a case report. J Altern Complement Med. 2002 ; 8 (4). 493-497
80. Miura T, Yuan L, Sun B, et al. Isoflavone aglycon produced by culture of soybean extracts with basidiomycetes and its anti-angiogenic activity. Biosci Biotechnol Biochem. 2002 ; 66 (12). 2626-2631
81. deVere White RW, Tsodikov A, Stapp EC, Soares SE, Fujii H, Hackman RM. Effects of a high dose, aglycone-rich soy extract on prostate-specific antigen and serum isoflavone concentrations in men with localized prostate cancer. Nutr Cancer. 2010 ; 62 (8). 1036-1043
82. Cheuk W, Chan JK, Nuovo G, Chan MK, Fok M. Regression of gastric large B-cell lymphoma accompanied by a florid lymphoma-like T-cell reaction: immunomodulatory effect of Ganoderma lucidum (Lingzhi)?. Int J Surg Pathol. 2007 ; 15 (2). 180-186
83. Wanachiwanawin D, Piankijagum A, Chaiprasert A, Lertlaituan P, Tungtrongchitr A, Chinabutr P. Ganoderma lucidum: a cause of pseudoparasitosis. Southeast Asian J Trop Med Public Health. 2006 ; 37 (6). 1099-1102
84. Yan B, Meng X, Shi J, Qin Z, Wei P, Lao L. Ganoderma lucidum spore induced CA72-4 elevation in gastrointestinal cancer: a five-case report. Integr Cancer Ther. 2014 ; 13 (2). 161-166
85. Liang Y, He M, Fan X, Ye W, Yang Z, Zhong R. An abnormal elevation of serum CA72-4 by Ganoderma lucidum spore powder. Ann Clin Lab Sci. 2013 ; 43 (3). 337-340
86. Suprasert P, Apichartpiyakul C, Sakonwasun C, Nitisuwanraksa P, Phuackchantuck R. Clinical characteristics of gynecologic cancer patients who respond to salvage treatment with Lingzhi. Asian Pac J Cancer Prev. 2014 ; 15 (10). 4193-4196